Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is not a standard combination therapy. Travoprost, latanoprost, and bimatoprost are three distinct prostaglandin analog medications used to treat glaucoma and ocular hypertension. Each reduces intraocular pressure (IOP) primarily by increasing uveoscleral outflow. Clinical studies have shown that these medications have similar mechanisms of action and comparable efficacy when used individually. While combinations of two prostaglandins (such as bimatoprost added to latanoprost or travoprost added to latanoprost) have shown additive effects in some studies, the use of all three simultaneously is not a standard clinical practice and may not provide additional benefits beyond using just one or two.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on travoprost + latanoprost + bimatoprost.